Autopsy report · NCT02689219

Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors

“lack of funding/ benefit”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 10 months before it stopped.
• 18 participants enrolled.
• Results were posted on the registry 10 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Nabil Adra

Sponsor type

University, hospital or other

Conditions

Germ Cell Tumors; Testis Cancer; Testicular Cancer; Embryonal Carcinoma; Nonseminomatous Germ Cell Tumor

Interventions

Brentuximab Vedotin

Participants

18

Sites

4

Countries

United States

Trials that died the same way

• Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults
  “Lack of funding” (90% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.